Author(s) :

Petru Vladimir, Marius.

Volume/Issue :

Abstract :

Lung cancer has benefited in the last decade from novel, efficient and targeted therapeutic advances such as immunotherapy, which allows for a more personalized approach of the oncologic treatment. However,up to this date, there is not a standardized method of determining the potential success of immunotherapy in spite of the existence of a variety of markers that are being studied for this purpose. We therefore aim to review the immune markers described in the literature in response to PD-1, PDL-1 and CTLA-4 immunotherapy and offer a more comprehensive picture of their utility, prognostic and predictive value.

No. of Downloads :

0